Concept Foundation, Geneva, Switzerland.
Maternal, Child and Adolescent Health Program, Burnet Institute, Melbourne, VIC, Australia.
Lancet Glob Health. 2024 Jul;12(7):e1174-e1183. doi: 10.1016/S2214-109X(24)00144-X.
We developed a comprehensive database of medicines that are used or are being investigated for pre-eclampsia or eclampsia, preterm birth or labour, postpartum haemorrhage, intrauterine growth restriction, and fetal distress and that were in active development between 2000 and 2021. A total of 444 candidates were identified: approximately half of candidates were in active development, two-thirds had been repurposed after initially being used for another condition, and just under half were in preclinical studies. Only 64 candidates were in active late-stage (phase 3) development as of Oct 25, 2021, and given the slow pace of biomedical development, it could take years before any of these products eventually make it to market. A lack of innovation for maternal health medicines persists, and the market continues to fail pregnant individuals. There is a need for collective action from all relevant stakeholders to accelerate investment in the development of new or improved medicines for pregnancy-related conditions.
我们开发了一个综合的药物数据库，其中包括用于或正在研究子痫前期或子痫、早产或分娩、产后出血、胎儿宫内生长受限以及胎儿窘迫的药物，这些药物在 2000 年至 2021 年间处于积极开发阶段。总共确定了 444 种候选药物：大约一半的候选药物处于积极开发阶段，三分之二的候选药物最初用于治疗其他疾病，近一半的候选药物处于临床前研究阶段。截至 2021 年 10 月 25 日，只有 64 种候选药物处于积极的晚期（第 3 阶段）开发阶段，鉴于生物医学发展缓慢，这些产品中的任何一种最终都可能需要数年时间才能上市。孕产妇健康药物的创新仍然缺乏，市场继续让孕妇失望。所有相关利益相关者都需要采取集体行动，加快投资于开发新的或改进的与妊娠相关疾病的药物。
